What is ixekizumab?
Ixekizumab (brand name Taltz) is a biologic medication used to treat psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a self-injectable medication administered at home using the Taltz autoinjector.
How it works
Ixekizumab is a monoclonal antibody that blocks interleukin-17A (IL-17A) — the same target as secukinumab (Cosentyx). IL-17A is a key protein that drives inflammation in psoriatic and spondylitic disease. By neutralizing IL-17A, ixekizumab reduces inflammation in the joints and skin without broadly suppressing the immune system.
How it’s given
Ixekizumab is self-administered as a subcutaneous (under the skin) injection:
- Starting dose: 160 mg at week 0 (given as two separate 80 mg injections)
- Maintenance phase: 80 mg every 4 weeks (monthly)
Dosing may vary depending on your specific condition. Your rheumatologist will determine the right schedule for you. Ixekizumab does not need to be combined with methotrexate.
Storage: Keep ixekizumab refrigerated. Allow it to reach room temperature before injecting for greater comfort.
What to expect when starting
Ixekizumab is known for its rapid onset of action. Some patients notice improvement in skin symptoms within 1 to 2 weeks. Joint symptoms typically begin to improve within 3 to 4 weeks. The higher initial dose helps the medication build to effective levels quickly.
Side effects to watch for
The most common side effects include:
- Injection site reactions — these can be more noticeable with ixekizumab than with some other biologics. Redness, swelling, pain, or itching at the injection site are common early on but typically improve over time as your body adjusts.
- Upper respiratory infections (cold-like symptoms)
- Nausea
Most side effects are mild. Contact your rheumatologist if you develop signs of infection such as fever, persistent cough, or symptoms that worry you.
Required screening before starting
Before beginning ixekizumab, your rheumatologist will order:
- Tuberculosis (TB) testing — standard for all biologic medications
Things to avoid
- Live vaccines should not be given while on ixekizumab. Inactivated vaccines (such as the flu shot) are safe and recommended.
Important: Like all IL-17 inhibitors, ixekizumab should not be used in patients with active inflammatory bowel disease (Crohn’s disease), as it can worsen IBD symptoms. If you have any history of bowel problems — including chronic diarrhea, bloody stools, or a known IBD diagnosis — discuss this with your rheumatologist before starting treatment.
Frequently asked questions
How is ixekizumab different from secukinumab (Cosentyx)? Both medications target the same protein (IL-17A) and treat the same conditions. The main differences are the dosing schedule and the injection device. Some patients respond better to one than the other, and your rheumatologist can help determine which is the best fit for you.
Will the injection site reactions get better? Yes. Injection site reactions are most common during the first few months of treatment and typically become less frequent and less bothersome over time.
Do I need to take methotrexate with ixekizumab? No. Ixekizumab works well on its own and does not require combination with methotrexate.
What if I miss a dose? Inject the missed dose as soon as you remember, then resume your regular schedule. If you are unsure about timing, contact your rheumatologist’s office.
Is this a long-term medication? Yes. Ixekizumab is typically continued as long as it is effective and well-tolerated. Stopping treatment may lead to a return of symptoms.
This handout is for informational purposes only and does not replace the advice of your rheumatologist. Always discuss your specific medical situation, including all medications and health conditions, with your provider before starting or changing any treatment.